tiprankstipranks
Trending News
More News >
TG Therapeutics (TGTX)
NASDAQ:TGTX

TG Therapeutics (TGTX) AI Stock Analysis

Compare
2,033 Followers

Top Page

TG

TG Therapeutics

(NASDAQ:TGTX)

Rating:65Neutral
Price Target:
$39.00
▲(6.21%Upside)
TG Therapeutics exhibits strong financial performance improvement and positive earnings call highlights, driving the score. The high P/E ratio and lack of dividend yield, along with neutral technical indicators, temper the overall evaluation. Positive momentum from the earnings call contributes significantly, but valuation concerns limit the stock's attractiveness.
Positive Factors
Market Expansion
Briumvi is now commercially available in additional countries in the EU, UK, and Switzerland, which could translate into incrementally larger royalty revenue in the quarters ahead.
Revenue Growth
TG Therapeutics reported $120MM of US net Briumvi revenue, representing +11% Q/Q growth driven by a combination of new and repeat prescriptions.
Stock Rating
Analyst maintains a Buy rating for TG Therapeutics stock, indicating confidence in its potential.
Negative Factors
Competition
Ocrevus Zunovo still remains bigger risk to Briumvi growth.
Prescription Growth
This is the first time repeat prescriptions have surpassed new prescriptions, potentially indicating a slowdown in new start growth.
Research and Development Spending
The higher R&D spend this quarter, driven by manufacturing expenses for subq Briumvi, also raised some eyebrows.

TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)

TG Therapeutics Business Overview & Revenue Model

Company DescriptionTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
How the Company Makes MoneyTG Therapeutics generates revenue through the sales of its pharmaceutical products, primarily focusing on innovative treatments for B-cell malignancies and autoimmune diseases. The company's revenue model is centered around the commercialization of its core products, which are developed through extensive research and clinical trials. Key revenue streams include product sales upon obtaining regulatory approval and entering the market. Additionally, TG Therapeutics may engage in strategic partnerships or collaborations with other pharmaceutical companies to enhance the development and distribution of its products, thereby contributing to its earnings. These partnerships may also involve licensing agreements, milestone payments, and royalties, which can provide additional financial support and revenue opportunities.

TG Therapeutics Earnings Call Summary

Earnings Call Date:May 05, 2025
(Q1-2025)
|
% Change Since: -15.47%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in BRIUMVI sales, increased revenue guidance, and advancements in the pipeline, suggesting strong commercial and financial performance. While there were some concerns about manufacturing expenses and potential tariffs, these were not expected to significantly impact overall performance.
Q1-2025 Updates
Positive Updates
BRIUMVI US Net Sales Growth
BRIUMVI US net sales reached nearly $120 million in the first quarter, exceeding expectations and marking a 137% year-over-year growth and 16% sequential quarter-over-quarter growth.
Raising Full-Year Revenue Guidance
Based on strong performance, TG Therapeutics raised their full-year 2025 US net revenue guidance for BRIUMVI to $560 million from a previous $525 million.
Pipeline and Innovation Strategy
TG Therapeutics is advancing a self-administered subcutaneous version of BRIUMVI and has initiated efforts in Myasthenia Gravis and azer-cel, a CD19 CAR-T cell therapy for progressive forms of MS.
Commercial Strategy Execution
The company reported strong commercial execution, with high repeat prescriptions and increasing prescriber confidence, leading to a robust start in 2025.
Financial Stability
TG Therapeutics ended the quarter with $276 million in cash, cash equivalents, and investment securities, indicating a strong financial position.
Negative Updates
Subcutaneous BRIUMVI Manufacturing Expenses
An increase in operating expenses was noted, primarily driven by $20 million in manufacturing investments for subcutaneous BRIUMVI.
Potential Tariff Concerns
There are ongoing discussions regarding potential tariffs as BRIUMVI is manufactured in South Korea, though the company does not expect a material impact on financial performance.
Company Guidance
During TG Therapeutics' first quarter 2025 conference call, the company reported strong financial performance, with BRIUMVI US net sales reaching approximately $119.7 million, reflecting a 137% year-over-year growth and 16% sequential quarter-over-quarter growth. This performance led to an increase in full-year 2025 US net revenue guidance from $525 million to $560 million. The company highlighted robust patient demand, with the highest months of new patient enrollment since launch, and a growing number of repeat prescriptions. The operating expenses for the quarter, excluding non-cash items, were about $82 million, tracking slightly ahead of the annual guidance of $300 million primarily due to manufacturing investments. The company reported a GAAP net income of approximately $5 million for the quarter, supported by a strong cash position of $276 million. Key strategic initiatives discussed included a direct-to-patient television campaign and ongoing development of a subcutaneous formulation of BRIUMVI, with plans to launch a pivotal trial this year.

TG Therapeutics Financial Statement Overview

Summary
TG Therapeutics exhibits a strong recovery trajectory with significant revenue and profit growth, alongside improved balance sheet metrics. However, the continued negative operating cash flow and historical financial instability present areas of concern. Overall, the company shows promise but faces challenges in achieving sustainable cash flow generation.
Income Statement
75
Positive
TG Therapeutics has demonstrated strong revenue growth with a significant increase from $278,500 in 2022 to $386.4 million in TTM (Trailing-Twelve-Months). The gross profit margin improved to 87.4% in TTM, and net profit margin also rose to 10.1%, signaling enhanced operational efficiency. However, the past losses in earlier years indicate historical instability.
Balance Sheet
68
Positive
The company has managed to improve its financial health with positive stockholders' equity of $237.3 million in TTM. The debt-to-equity ratio is low at 0.038, indicating low leverage. However, the equity ratio of 36.1% suggests moderate reliance on liabilities, and past negative equity highlights previous financial distress.
Cash Flow
60
Neutral
The operating cash flow remains negative at -$61 million in TTM, though free cash flow has shown improvement. The company's ability to convert net income into cash flow is limited, posing a risk to liquidity despite substantial financing activities that sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue386.39M329.00M233.66M2.79M6.69M152.00K
Gross Profit337.80M290.52M219.11M2.52M5.90M-222.00K
EBITDA70.06M49.90M26.10M-187.63M-341.97M-272.68M
Net Income39.15M23.38M12.67M-203.83M-355.55M-285.88M
Balance Sheet
Total Assets656.69M577.69M329.59M193.57M379.63M625.64M
Cash, Cash Equivalents and Short-Term Investments276.24M311.00M217.51M174.08M350.30M605.43M
Total Debt254.58M254.38M110.80M83.06M79.05M41.98M
Total Liabilities419.40M355.33M169.09M134.99M142.48M106.29M
Stockholders Equity237.29M222.36M160.50M-1.53B-1.33B519.35M
Cash Flow
Free Cash Flow-61.09M-40.56M-31.41M-176.18M-296.04M-214.86M
Operating Cash Flow-61.02M-40.52M-31.41M-176.17M-295.63M-214.51M
Investing Cash Flow-4.71M-1.04M-50.65M-20.01M-332.00K-24.51M
Financing Cash Flow122.42M128.53M72.70M-391.00K41.42M679.83M

TG Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price36.72
Price Trends
50DMA
37.04
Negative
100DMA
36.67
Positive
200DMA
32.69
Positive
Market Momentum
MACD
-0.10
Positive
RSI
50.43
Neutral
STOCH
43.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 36.72 is below the 20-day moving average (MA) of 37.12, below the 50-day MA of 37.04, and above the 200-day MA of 32.69, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 43.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.

TG Therapeutics Risk Analysis

TG Therapeutics disclosed 74 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

TG Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$4.13B34.4613.90%247.53%118.34%
65
Neutral
$5.83B150.4919.70%33.54%-6.13%
56
Neutral
$6.61B-20.00%112.46%54.33%
53
Neutral
$1.79B19.61-23.61%59.15%-1881.09%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
50
Neutral
$8.30B-47.71%99.19%48.43%
49
Neutral
$5.19B-282.16%72.16%9.65%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TGTX
TG Therapeutics
36.72
17.17
87.83%
SRPT
Sarepta Therapeutics
18.24
-133.24
-87.96%
BPMC
Blueprint Medicines
128.35
12.03
10.34%
AXSM
Axsome Therapeutics
105.44
21.82
26.09%
KRYS
Krystal Biotech
143.08
-48.21
-25.20%
LEGN
Legend Biotech
35.64
-11.77
-24.83%

TG Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
TG Therapeutics Approves Key Proposals at Annual Meeting
Neutral
Jun 13, 2025

On June 12, 2025, TG Therapeutics, Inc. held its Annual Meeting where stockholders representing 74.58% of the outstanding shares were present. All proposals, including the election of six directors, ratification of KPMG LLP as the independent auditor, approval of executive compensation, and amendment to the 2022 Incentive Plan, were approved, potentially impacting the company’s governance and financial strategies.

The most recent analyst rating on (TGTX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025